After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Noblesville-based Diamond Charts LLC has become a huge hit among college baseball teams big and small since two Rose-Hulman Institute of Technology alumni launched it in early 2013 with $200 and what seemed like a crazy idea.
Anthem Blue Cross and Blue Shield has added St. Vincent Health to the “narrow network” of health care providers it uses for Obamacare plans. St. Vincent’s 22 hospitals and nearly 900 physicians on June 1 joined the network Anthem uses for individual health plans it sells on the online exchange created by the Affordable Care […]
Axovant Sciences Ltd., a company without a finished product or a dime of sales, has an almost $3 billion valuation after its public-market debut. The IPO shows the staggering potential for any company that can develop a successful Alzheimer’s treatment.
Eli Lilly stock rose 5.4 percent per share on Tuesday, its biggest daily increase since March 2009, after Elanco President Jeffrey Simmons was asked if Lilly might one day shed the unit in an initial public offering.
Lilly’s basal insulin peglispro proved more effective than the $7 billion blockbuster Lantus at controlling diabetics’ blood sugar, but it also had greater effect on patients’ livers and hearts. Analysts are unsure of its future.
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
Assets in 2014 rose from $7.7 billion to $10.1 billion, a 31-percent surge. The value of the endowment now has nearly doubled since closing 2010 at $5.3 billion.
Conner Prairie President and CEO Ellen Rosenthal has led tremendous growth at the interactive history park in Fishers since 2003. She plans to retire at the end of the year.
Eli Lilly and Co. signed yet another partnership aimed at developing immune-oncology drugs. The Indianapolis-based drugmaker formed a collaboration with U.K.-based AstraZeneca plc to collaborate on a Phase 1 clinical trial for patients with advanced solid tumors. The test will study the effect of giving patients Lilly’s drug Cryamza in combination with AstraZeneca’s experimental drug […]
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
The city has a chance to once again become known for innovation. But only if it can avoid serious missteps like the one we saw earlier this year with the Religious Freedom Restoration Act.
The drugmaker plans to sell 2.1 billion euros ($2.3 billion) of securities in three parts, according to a person familiar with the matter who asked not to be identified.
Christ Church Cathedral sued JPMorgan last year, saying the bank selected unsuitable and poorly performing investments, causing the church trusts to lose $13 million in value from 2004 to 2013.
